[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse ENTPD2

Summary
SymbolENTPD2
Nameectonucleoside triphosphate diphosphohydrolase 2
Aliases NTPDase-2; CD39-like-1; ecto-ATPase; CD39L1; CD39 antigen-like 1; NTPDase 2; ecto-ATP diphosphohydrolase 2; ......
Chromosomal Location9q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform Long: Cell membrane; Multi-pass membrane protein.; SUBCELLULAR LOCATION: Isoform Short: Endoplasmic reticulum membrane; Multi-pass membrane protein.; SUBCELLULAR LOCATION: Isoform gamma: Endoplasmic reticulum membrane; Multi-pass membrane protein.
Domain PF01150 GDA1/CD39 (nucleoside phosphatase) family
Function

In the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Hydrolyzes ADP only to a marginal extent. The order of activity with different substrates is ATP > GTP > CTP = ITP > UTP >> ADP = UDP.

> Gene Ontology
 
Biological Process GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0009132 nucleoside diphosphate metabolic process
GO:0009134 nucleoside diphosphate catabolic process
GO:0009135 purine nucleoside diphosphate metabolic process
GO:0009137 purine nucleoside diphosphate catabolic process
GO:0009179 purine ribonucleoside diphosphate metabolic process
GO:0009181 purine ribonucleoside diphosphate catabolic process
GO:0009185 ribonucleoside diphosphate metabolic process
GO:0009191 ribonucleoside diphosphate catabolic process
GO:0019439 aromatic compound catabolic process
GO:0030168 platelet activation
GO:0034655 nucleobase-containing compound catabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0046434 organophosphate catabolic process
GO:0046700 heterocycle catabolic process
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:1901292 nucleoside phosphate catabolic process
GO:1901361 organic cyclic compound catabolic process
Molecular Function GO:0017110 nucleoside-diphosphatase activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0005605 basal lamina
GO:0044420 extracellular matrix component
> KEGG and Reactome Pathway
 
KEGG hsa04742 Taste transduction
hsa00230 Purine metabolism
Reactome R-HSA-1430728: Metabolism
R-HSA-15869: Metabolism of nucleotides
R-HSA-8850843: Phosphate bond hydrolysis by NTPDase proteins
Summary
SymbolENTPD2
Nameectonucleoside triphosphate diphosphohydrolase 2
Aliases NTPDase-2; CD39-like-1; ecto-ATPase; CD39L1; CD39 antigen-like 1; NTPDase 2; ecto-ATP diphosphohydrolase 2; ......
Chromosomal Location9q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ENTPD2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ENTPD2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28894087Hepatocellular CarcinomaInhibit immunityMechanistically, we demonstrate that ENTPD2 converts extracellular ATP to 5'-AMP, which prevents the differentiation of MDSCs and therefore promotes the maintenance of MDSCs. We further find that ENTPD2 inhibition is able to mitigate cancer growth and enhance the efficiency and efficacy of immune checkpoint inhibitors.
Summary
SymbolENTPD2
Nameectonucleoside triphosphate diphosphohydrolase 2
Aliases NTPDase-2; CD39-like-1; ecto-ATPase; CD39L1; CD39 antigen-like 1; NTPDase 2; ecto-ATP diphosphohydrolase 2; ......
Chromosomal Location9q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ENTPD2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolENTPD2
Nameectonucleoside triphosphate diphosphohydrolase 2
Aliases NTPDase-2; CD39-like-1; ecto-ATPase; CD39L1; CD39 antigen-like 1; NTPDase 2; ecto-ATP diphosphohydrolase 2; ......
Chromosomal Location9q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ENTPD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0740.843
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7880.219
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.7040.193
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1060.858
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9080.525
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8960.559
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.9570.105
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2810.811
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.8230.12
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.0950.285
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.1010.407
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3290.176
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ENTPD2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolENTPD2
Nameectonucleoside triphosphate diphosphohydrolase 2
Aliases NTPDase-2; CD39-like-1; ecto-ATPase; CD39L1; CD39 antigen-like 1; NTPDase 2; ecto-ATP diphosphohydrolase 2; ......
Chromosomal Location9q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ENTPD2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolENTPD2
Nameectonucleoside triphosphate diphosphohydrolase 2
Aliases NTPDase-2; CD39-like-1; ecto-ATPase; CD39L1; CD39 antigen-like 1; NTPDase 2; ecto-ATP diphosphohydrolase 2; ......
Chromosomal Location9q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ENTPD2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ENTPD2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolENTPD2
Nameectonucleoside triphosphate diphosphohydrolase 2
Aliases NTPDase-2; CD39-like-1; ecto-ATPase; CD39L1; CD39 antigen-like 1; NTPDase 2; ecto-ATP diphosphohydrolase 2; ......
Chromosomal Location9q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ENTPD2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolENTPD2
Nameectonucleoside triphosphate diphosphohydrolase 2
Aliases NTPDase-2; CD39-like-1; ecto-ATPase; CD39L1; CD39 antigen-like 1; NTPDase 2; ecto-ATP diphosphohydrolase 2; ......
Chromosomal Location9q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ENTPD2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolENTPD2
Nameectonucleoside triphosphate diphosphohydrolase 2
Aliases NTPDase-2; CD39-like-1; ecto-ATPase; CD39L1; CD39 antigen-like 1; NTPDase 2; ecto-ATP diphosphohydrolase 2; ......
Chromosomal Location9q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ENTPD2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolENTPD2
Nameectonucleoside triphosphate diphosphohydrolase 2
Aliases NTPDase-2; CD39-like-1; ecto-ATPase; CD39L1; CD39 antigen-like 1; NTPDase 2; ecto-ATP diphosphohydrolase 2; ......
Chromosomal Location9q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ENTPD2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.